<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE299nnn/GSE299164/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299164</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Pharmacological Activation of the LXR-APOE Axis by RGX-104 Attenuates Pulmonary Fibrosis through LRP1 and PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition</name><description>Idiopathic pulmonary fibrosis (IPF), a fatal interstitial lung disease with limited therapeutic options, urgently requires novel strategies targeting upstream fibrogenic drivers. Through integrated meta-analysis of seven plasma cohorts and two-sample Mendelian randomization (MR), we identified apolipoprotein E (APOE) as a robust protective factor against IPF, with genetically elevated APOE levels correlating positively with pulmonary function. Plasma APOE depletion in IPF patients demonstrated superior diagnostic accuracy. CRISPR-engineered APOE-deficient canines spontaneously developed pulmonary fibrotic lesions, whereas Apoe‒/‒ mice exhibited exacerbated bleomycin-induced fibrosis, which was reversed by recombinant APOE protein administration. Single-cell transcriptomics revealed fibroblast-specific enrichment of the APOE receptor LRP1, and SPIDER technology coupled with surface plasmon resonance (SPR) identified PLAU as a novel high-affinity APOE interactor. Mechanistically, APOE suppressed TGF-β/Smad-driven fibroblast activation through dual receptor co-engagement (LRP1 and PLAU), attenuating α-SMA, collagen 1, and fibronectin expression. Pharmacological activation of the LXR‒APOE axis via RGX‒104, a small-molecule LXR agonist, rescued Apoe expression, reduced collagen deposition in murine models, and mitigated fibrotic marker expression in human precision-cut lung slices. This work establishes APOE as a causal guardian against fibrogenesis via LRP1/PLAU-mediated TGF-β/Smad inhibition, bridging genetic epidemiology with therapeutic discovery. Our cross-species validation and mechanistic elucidation position RGX-104 as a promising candidate for clinical translation in IPF.</description><dates><publication>2026/09/09</publication></dates><accession>GSE299164</accession><cross_references><GSM>GSM9034730</GSM><GSM>GSM9034723</GSM><GSM>GSM9034722</GSM><GSM>GSM9034721</GSM><GSM>GSM9034731</GSM><GSM>GSM9034720</GSM><GSM>GSM9034727</GSM><GSM>GSM9034726</GSM><GSM>GSM9034725</GSM><GSM>GSM9034724</GSM><GSM>GSM9034729</GSM><GSM>GSM9034728</GSM><GPL>34284</GPL><GSE>299164</GSE><taxon>Homo sapiens</taxon><PMID>[41475664]</PMID></cross_references></HashMap>